Roundtable Discussion: Advancing Patient Selection & Monitoring Across Therapeutics Modalities in Precision Oncology for Improved Clinical Outcomes
Time: 4:10 pm
day: Day 1 - Track A (2)
Details:
- How can you optimise the use of tumour and blood-based biomarkers for dynamic patient selection and treatment monitoring in oncology clinical trials? How does this vary between therapeutic modality?
- Addressing the challenge of biomarker heterogeneity within solid tumors and its impact on accurate patient stratification for oncology therapies
- Why is biomarker assay standardisation critical for clinical adoption, and what collaborative efforts between biopharma, diagnostics, and regulatory agencies can streamline this process?
